Jyoti Bajpai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jyoti Bajpai has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Surya Kant
Professor,Department of Respiratory Medicine KGMU, Lucknow District, India
16 shared publications- Surya Kant
Department of Respiratory Medicine, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
12 shared publications - Ajay Kumar Verma
King George’s Medical University, Lucknow, Uttar Pradesh, India
9 shared publications Ajay Kumar Verma
7 shared publicationsAkshyaya Pradhan
Professor, Department of cardiology, King George Medical University,U.P.,Lucknow, Lucknow District, India
7 shared publications- Akshyaya Pradhan
Department of Cardiology, King George’s Medical University, Lucknow, India
6 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (5) , 73
Efficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with high morbidity and mortality. Inhaled treprostinil showed pulmonary vascular and lung-function signals in pulmonary hypertension associated with Interstitial lung disease (PH-ILD) and was subsequently tested in IPF trials. Objectives: This systematic review and meta-analysis assessed the efficacy and safety of inhaled treprostinil in adults with IPF. Methods: PubMed, Google Scholar and the Cochrane Library/CENTRAL were searched for records published from January 2000 to 2026. A random-effects meta-analysis used the DerSimonian–Laird tau squared and inverse-variance weighting methods. Continuous outcomes were pooled as generic inverse-variance effects from reported estimates and 95% confidence intervals. Hazard ratios were pooled on the log scale. Safety outcomes were pooled as risk ratios from event counts. Results: The searches identified 1552 records. After deduplication, 379 records were screened and 85 full-text reports were assessed. Eleven reports were included in the systematic review. TETON-1 and TETON-2 were the two direct-IPF randomized trials within the coordinated TETON program eligible for primary meta-analysis. Inhaled treprostinil improved absolute forced vital capacity (FVC) change at 52 weeks compared with placebo (MD 111.28 mL, 95% CI 77.61 to 144.95, p < 0.001; I squared 8.5%). Clinical worsening was reduced (HR 0.69, 95% CI 0.57 to 0.84, p < 0.001; I squared 0.0%). Acute exacerbation was lower in pooled analysis (HR 0.52, 95% CI 0.30 to 0.91, p = 0.022), while all-cause mortality did not differ significantly (HR 0.70, 95% CI 0.47 to 1.05, p = 0.086). Adverse-event discontinuation, cough and headache were more frequent with treprostinil. Conclusions: In direct IPF randomized evidence, inhaled treprostinil preserved lung function and reduced clinical worsening at 52 weeks.
- 8 October 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (5) , 73
Open AccessEfficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with high morbidity and mortality. Inhaled treprostinil showed pulmonary vascular and lung-function signals in pulmonary hypertension associated with Interstitial lung disease (PH-ILD) and was subsequently tested in IPF trials. Objectives: This systematic review and meta-analysis assessed the efficacy and safety of inhaled treprostinil in adults with IPF. Methods: PubMed, Google Scholar and the Cochrane Library/CENTRAL were searched for records published from January 2000 to 2026. A random-effects meta-analysis used the DerSimonian–Laird tau squared and inverse-variance weighting methods. Continuous outcomes were pooled as generic inverse-variance effects from reported estimates and 95% confidence intervals. Hazard ratios were pooled on the log scale. Safety outcomes were pooled as risk ratios from event counts. Results: The searches identified 1552 records. After deduplication, 379 records were screened and 85 full-text reports were assessed. Eleven reports were included in the systematic review. TETON-1 and TETON-2 were the two direct-IPF randomized trials within the coordinated TETON program eligible for primary meta-analysis. Inhaled treprostinil improved absolute forced vital capacity (FVC) change at 52 weeks compared with placebo (MD 111.28 mL, 95% CI 77.61 to 144.95, p < 0.001; I squared 8.5%). Clinical worsening was reduced (HR 0.69, 95% CI 0.57 to 0.84, p < 0.001; I squared 0.0%). Acute exacerbation was lower in pooled analysis (HR 0.52, 95% CI 0.30 to 0.91, p = 0.022), while all-cause mortality did not differ significantly (HR 0.70, 95% CI 0.47 to 1.05, p = 0.086). Adverse-event discontinuation, cough and headache were more frequent with treprostinil. Conclusions: In direct IPF randomized evidence, inhaled treprostinil preserved lung function and reduced clinical worsening at 52 weeks.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1413
Association of LOX-1 and Lipoprotein(a) with Obstructive Sleep Apnea and Metabolic Parameters: A Case–Control Study
Background: Obstructive sleep apnea (OSA) is associated with metabolic dysfunction and increased cardiovascular risk. Lectin-like oxidized LDL receptor-1 (LOX-1) and lipoprotein(a) [LPA] are emerging biomarkers implicated in atherosclerosis. We aimed to evaluate their association with OSA severity and metabolic parameters. Methods: In this case-control study, 90 participants were enrolled (60 OSA patients, 30 controls). Anthropometric, biochemical, and polysomnographic (PSG) parameters were recorded. LOX-1 and LPA levels were measured and compared between groups. Correlation, linear regression, and logistic regression analyses were performed to determine associations and independent predictors. Results: OSA patients were older (median 50 vs 39 years, p<0.001) and had significantly higher BMI (33.45±5.01 vs 24.14±2.90 kg/m², p<0.001) and neck circumference (p<0.001). HDL was lower, while LDL, fasting glucose, and HbA1c were significantly higher in OSA (p<0.01). LOX-1 levels were significantly elevated in OSA compared to controls (p<0.001), whereas LPA levels did not differ significantly. LOX-1 showed a positive correlation with triglycerides (ρ=0.44, p<0.001) but not with AHI or other PSG parameters. LPA showed no significant correlation with metabolic or PSG variables. In a detailed analysis, LOX-1, age, and BMI were found to be independently related to OSA, meaning that higher levels of these factors increase the likelihood of having the condition. Conclusion: LOX-1 is higher in OSA and linked to the disease, while LPA is not, indicating that LOX-1 might help assess the risk of heart and metabolic
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA1413
Association of LOX-1 and Lipoprotein(a) with Obstructive Sleep Apnea and Metabolic Parameters: A Case–Control Study
Background: Obstructive sleep apnea (OSA) is associated with metabolic dysfunction and increased cardiovascular risk. Lectin-like oxidized LDL receptor-1 (LOX-1) and lipoprotein(a) [LPA] are emerging biomarkers implicated in atherosclerosis. We aimed to evaluate their association with OSA severity and metabolic parameters. Methods: In this case-control study, 90 participants were enrolled (60 OSA patients, 30 controls). Anthropometric, biochemical, and polysomnographic (PSG) parameters were recorded. LOX-1 and LPA levels were measured and compared between groups. Correlation, linear regression, and logistic regression analyses were performed to determine associations and independent predictors. Results: OSA patients were older (median 50 vs 39 years, p<0.001) and had significantly higher BMI (33.45±5.01 vs 24.14±2.90 kg/m², p<0.001) and neck circumference (p<0.001). HDL was lower, while LDL, fasting glucose, and HbA1c were significantly higher in OSA (p<0.01). LOX-1 levels were significantly elevated in OSA compared to controls (p<0.001), whereas LPA levels did not differ significantly. LOX-1 showed a positive correlation with triglycerides (ρ=0.44, p<0.001) but not with AHI or other PSG parameters. LPA showed no significant correlation with metabolic or PSG variables. In a detailed analysis, LOX-1, age, and BMI were found to be independently related to OSA, meaning that higher levels of these factors increase the likelihood of having the condition. Conclusion: LOX-1 is higher in OSA and linked to the disease, while LPA is not, indicating that LOX-1 might help assess the risk of heart and metabolic
- Open Access
- 11 August 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (4) , 59
Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study
Purpose: Pulmonary hypertension (PH) is a serious complication of COPD associated with worse outcomes. Reliable circulating biomarkers of pulmonary vascular involvement are lacking. Angiopoietin-1 (ANGP-1) and angiopoietin-2 (ANGP-2) regulate endothelial homeostasis, but their relationship with echocardiographically estimated pulmonary pressure in COPD remains uncertain. Methods: This prospective cross-sectional study included 70 consecutively recruited adults with COPD, stratified using a study-specific echocardiographic threshold into the COPD PH group (mPAP > 20 mmHg; n = 46) and the COPD without PH (mPAP < 20 mmHg; n = 24), together with 20 additional controls. This non-invasive stratification was not considered equivalent to PH confirmed by right heart catheterization. Serum ANGP-1 and ANGP-2 were measured using ELISA. Group differences and associations with e-mPAP and right atrial pressure (RAP) were assessed. Results: Median ANGP-1 was higher in the elevated e-mPAP group [8780.06 (IQR 7955.29–9902.88) pg/mL] than in the lower e-mPAP group [3065.14 (1170.69–6200.41)] and controls [2997.19 (1292.13–3278.18); p < 0.001]. ANGP-2 showed a similar pattern [6152.92 (5380.27–8652.50), 2669.77 (1802.18–4744.00), and 2405.54 (1779.73–3751.76) pg/mL; p < 0.001]. Among COPD participants, ANGP-1 and ANGP-2 correlated with e-mPAP (r = 0.64 and r = 0.54) and RAP (r = 0.54 and r = 0.52; all Holm-adjusted p < 0.001). In multivariable models, e-mPAP and RAP were independently associated with ANGP-1, whereas RAP was independently associated with ANGP-2. Conclusions: Higher circulating ANGP-1 and ANGP-2 were associated with an elevated echo-estimated pulmonary-pressure phenotype in COPD. These findings are exploratory and require validation in larger cohorts using direct hemodynamic assessment.
- 11 August 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (4) , 59
Open AccessSerum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study
Purpose: Pulmonary hypertension (PH) is a serious complication of COPD associated with worse outcomes. Reliable circulating biomarkers of pulmonary vascular involvement are lacking. Angiopoietin-1 (ANGP-1) and angiopoietin-2 (ANGP-2) regulate endothelial homeostasis, but their relationship with echocardiographically estimated pulmonary pressure in COPD remains uncertain. Methods: This prospective cross-sectional study included 70 consecutively recruited adults with COPD, stratified using a study-specific echocardiographic threshold into the COPD PH group (mPAP > 20 mmHg; n = 46) and the COPD without PH (mPAP < 20 mmHg; n = 24), together with 20 additional controls. This non-invasive stratification was not considered equivalent to PH confirmed by right heart catheterization. Serum ANGP-1 and ANGP-2 were measured using ELISA. Group differences and associations with e-mPAP and right atrial pressure (RAP) were assessed. Results: Median ANGP-1 was higher in the elevated e-mPAP group [8780.06 (IQR 7955.29–9902.88) pg/mL] than in the lower e-mPAP group [3065.14 (1170.69–6200.41)] and controls [2997.19 (1292.13–3278.18); p < 0.001]. ANGP-2 showed a similar pattern [6152.92 (5380.27–8652.50), 2669.77 (1802.18–4744.00), and 2405.54 (1779.73–3751.76) pg/mL; p < 0.001]. Among COPD participants, ANGP-1 and ANGP-2 correlated with e-mPAP (r = 0.64 and r = 0.54) and RAP (r = 0.54 and r = 0.52; all Holm-adjusted p < 0.001). In multivariable models, e-mPAP and RAP were independently associated with ANGP-1, whereas RAP was independently associated with ANGP-2. Conclusions: Higher circulating ANGP-1 and ANGP-2 were associated with an elevated echo-estimated pulmonary-pressure phenotype in COPD. These findings are exploratory and require validation in larger cohorts using direct hemodynamic assessment.
- 10 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-11
Oxidative stress, antioxidant depletion, and DNA damage in post-COVID-19 patients: evidence of a disrupted redox network and loss of age-dependent antioxidant compensation
The relationship between oxidative stress and viral infections is well established, yet data on the redox consequences of COVID-19 beyond the acute phase remain sparse. We conducted a comprehensive assessment of oxidative stress biomarkers, antioxidant defences, and DNA damage in post-COVID patients, and examined whether COVID-19 infection disrupts the normal architecture of the antioxidant network. In this single-centre, cross-sectional, case–control study, 40 symptomatic post-COVID patients and 40 age- and sex-matched healthy controls were recruited from the Department of Respiratory Medicine, King George’s Medical University, Lucknow, India. Blood levels of lipid peroxidation (LPO), total antioxidant activity (TAA), superoxide dismutase (SOD), and glutathione reductase (GR) were measured. DNA damage was quantified using the alkaline comet assay. Data were analysed using Mann–Whitney U tests and Spearman rank correlations. Post-COVID patients showed profound antioxidant depletion: TAA was reduced by 60.8% (median 51.7 vs 224.3 mM; p < 0.001; Cohen’s d = 1.57), SOD by 34.0% (p < 0.001; d = 0.58), and GR by 35.0% (p < 0.001; d = 0.65). LPO was elevated but did not reach significance after correction for non-normality (p = 0.254), though it correlated significantly with radiographic severity (ρ = 0.403; p = 0.010) and was markedly elevated in patients with neurological involvement (2486.6 nmole/ml; p = 0.008). DNA damage was significantly increased across all comet parameters (% Tail DNA: + 24.0%; p < 0.001; d = 0.82). A novel finding was that the physiological age-dependent increase in TAA observed in controls (ρ = 0.425; p = 0.006) was abolished in patients (ρ = − 0.061; p = 0.707). Inter-marker correlation analysis revealed a rewiring of the antioxidant network, with breakdown of the normal LPO–TAA feedback relationship and emergence of SOD–TAA co-depletion. Post-COVID patients exhibit severe antioxidant depletion, significant DNA damage, and disruption of the normal redox network architecture. These findings provide a biochemical rationale for antioxidant-targeted therapeutic strategies in post-COVID management.
- 10 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-11
Oxidative stress, antioxidant depletion, and DNA damage in post-COVID-19 patients: evidence of a disrupted redox network and loss of age-dependent antioxidant compensation
The relationship between oxidative stress and viral infections is well established, yet data on the redox consequences of COVID-19 beyond the acute phase remain sparse. We conducted a comprehensive assessment of oxidative stress biomarkers, antioxidant defences, and DNA damage in post-COVID patients, and examined whether COVID-19 infection disrupts the normal architecture of the antioxidant network. In this single-centre, cross-sectional, case–control study, 40 symptomatic post-COVID patients and 40 age- and sex-matched healthy controls were recruited from the Department of Respiratory Medicine, King George’s Medical University, Lucknow, India. Blood levels of lipid peroxidation (LPO), total antioxidant activity (TAA), superoxide dismutase (SOD), and glutathione reductase (GR) were measured. DNA damage was quantified using the alkaline comet assay. Data were analysed using Mann–Whitney U tests and Spearman rank correlations. Post-COVID patients showed profound antioxidant depletion: TAA was reduced by 60.8% (median 51.7 vs 224.3 mM; p < 0.001; Cohen’s d = 1.57), SOD by 34.0% (p < 0.001; d = 0.58), and GR by 35.0% (p < 0.001; d = 0.65). LPO was elevated but did not reach significance after correction for non-normality (p = 0.254), though it correlated significantly with radiographic severity (ρ = 0.403; p = 0.010) and was markedly elevated in patients with neurological involvement (2486.6 nmole/ml; p = 0.008). DNA damage was significantly increased across all comet parameters (% Tail DNA: + 24.0%; p < 0.001; d = 0.82). A novel finding was that the physiological age-dependent increase in TAA observed in controls (ρ = 0.425; p = 0.006) was abolished in patients (ρ = − 0.061; p = 0.707). Inter-marker correlation analysis revealed a rewiring of the antioxidant network, with breakdown of the normal LPO–TAA feedback relationship and emergence of SOD–TAA co-depletion. Post-COVID patients exhibit severe antioxidant depletion, significant DNA damage, and disruption of the normal redox network architecture. These findings provide a biochemical rationale for antioxidant-targeted therapeutic strategies in post-COVID management.
- Open Access
- 26 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 18 (1)
Pulmonary hypertension in patients with obstructive sleep apnea: Correlation with disease severity and quality of life
BACKGROUND Obstructive sleep apnea (OSA) is increasingly recognized as a contributor to cardiovascular morbidity, including pulmonary hypertension (PH). AIM To assess the prevalence and severity of PH in newly diagnosed OSA patients and evaluate its association with disease severity and quality of life (QoL). METHODS In this cross-sectional study, 113 patients newly diagnosed with OSA underwent echocardiography to assess pulmonary artery pressures and completed the World Health Organisation Quality of Life Brief Version (WHOQOL-BREF) questionnaire. OSA severity was determined via polysomnography using the apnea-hypopnea index (AHI). Statistical correlations between AHI, right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (MPAP), and QoL domains were analyzed. RESULTS PH (defined by MPAP ≥ 20 mmHg) was observed in 71.68% of patients (MPAP ≥ 20 mmHg). Its prevalence increased with age and OSA severity (P < 0.01). The mean RVSP (39.4 mmHg in males vs 34.1 mmHg in females) and MPAP (27.76 mmHg in males vs 24.64 mmHg in females) values were slightly higher in males but the difference was not statistically significant. AHI and oxygen desaturation index positively correlated with RVSP (r = 0.677) and MPAP (r = 0.543). The WHOQOL-BREF scores were significantly lower in PH patients, particularly in physical and psychological domains (P < 0.01). CONCLUSION PH in OSA is strongly linked to disease severity, impairs right ventricular function, and reduces QoL. Findings are limited by the cross-sectional design and reliance on echocardiography instead of right heart catheterization.
- 26 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 18 (1)
Open AccessPulmonary hypertension in patients with obstructive sleep apnea: Correlation with disease severity and quality of life
BACKGROUND Obstructive sleep apnea (OSA) is increasingly recognized as a contributor to cardiovascular morbidity, including pulmonary hypertension (PH). AIM To assess the prevalence and severity of PH in newly diagnosed OSA patients and evaluate its association with disease severity and quality of life (QoL). METHODS In this cross-sectional study, 113 patients newly diagnosed with OSA underwent echocardiography to assess pulmonary artery pressures and completed the World Health Organisation Quality of Life Brief Version (WHOQOL-BREF) questionnaire. OSA severity was determined via polysomnography using the apnea-hypopnea index (AHI). Statistical correlations between AHI, right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (MPAP), and QoL domains were analyzed. RESULTS PH (defined by MPAP ≥ 20 mmHg) was observed in 71.68% of patients (MPAP ≥ 20 mmHg). Its prevalence increased with age and OSA severity (P < 0.01). The mean RVSP (39.4 mmHg in males vs 34.1 mmHg in females) and MPAP (27.76 mmHg in males vs 24.64 mmHg in females) values were slightly higher in males but the difference was not statistically significant. AHI and oxygen desaturation index positively correlated with RVSP (r = 0.677) and MPAP (r = 0.543). The WHOQOL-BREF scores were significantly lower in PH patients, particularly in physical and psychological domains (P < 0.01). CONCLUSION PH in OSA is strongly linked to disease severity, impairs right ventricular function, and reduces QoL. Findings are limited by the cross-sectional design and reliance on echocardiography instead of right heart catheterization.
- Open Access
- 24 October 2025
- Published by Wolters Kluwer Health in Lung India
- Vol. 42 (6) , 483-484
Diabetes and tuberculosis: A syndemic India cannot afford to ignore
- 24 October 2025
- Published by Wolters Kluwer Health in Lung India
- Vol. 42 (6) , 483-484
Open AccessDiabetes and tuberculosis: A syndemic India cannot afford to ignore
- Open Access
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (3) , 102688
Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation
Pulmonary arterial hypertension (PAH) is a progressive disease marked by degeneration of the lung’s blood vessels. As the disease progresses, the resistance to blood flow in the pulmonary arteries increases, putting a strain on the right side of the heart as it pumps blood through the lungs. PAH is characterized by changes in the structure of blood vessels and excessive cell growth. Untreated PAH leads to irreversible right-sided heart failure, often despite medical intervention. Patients experience a gradual decline in function until they are unable to perform daily activities. Advances in treatment have improved the prognosis for many PAH patients. Currently approved therapies target the prostacyclin, endothelin, nitric oxide, or phosphodiesterase pathways to slow the progression of the disease. To address the unmet need for effective PAH therapies, research efforts are focused on identifying new targets and developing therapies that specifically address the underlying disease mechanisms and restore vascular wall homeostasis. Among these, sotatercept, a fusion protein that targets the transforming growth factor-β superfamily signaling pathway, has emerged as a promising therapeutic option. In this review, we examine the available evidence from clinical trials to assess the potential of sotatercept as a treatment for PAH.
- 20 September 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (3) , 102688
Open AccessSotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation
Pulmonary arterial hypertension (PAH) is a progressive disease marked by degeneration of the lung’s blood vessels. As the disease progresses, the resistance to blood flow in the pulmonary arteries increases, putting a strain on the right side of the heart as it pumps blood through the lungs. PAH is characterized by changes in the structure of blood vessels and excessive cell growth. Untreated PAH leads to irreversible right-sided heart failure, often despite medical intervention. Patients experience a gradual decline in function until they are unable to perform daily activities. Advances in treatment have improved the prognosis for many PAH patients. Currently approved therapies target the prostacyclin, endothelin, nitric oxide, or phosphodiesterase pathways to slow the progression of the disease. To address the unmet need for effective PAH therapies, research efforts are focused on identifying new targets and developing therapies that specifically address the underlying disease mechanisms and restore vascular wall homeostasis. Among these, sotatercept, a fusion protein that targets the transforming growth factor-β superfamily signaling pathway, has emerged as a promising therapeutic option. In this review, we examine the available evidence from clinical trials to assess the potential of sotatercept as a treatment for PAH.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in The Journal of Association of Chest Physicians
- Vol. 13 (1) , 3-6
Hydropneumothorax Caused by Acinetobacter junii in an Immunocompetent Patient with No Comorbidities: A Rare Case Report
Acinetobacter junii, a rare human pathogen, poses a challenge in identification due to its complex diagnostic requirements. While generally nonfatal, it can lead to severe infections, often affecting immunocompromised individuals. We present a case of a 32-year-old nonsmoking make farmer with a 6-year history of progressive breathlessness, cough, and right-sided chest pain. Diagnosed with right-sided pneumothorax, the patient underwent pigtail and Mallecot’s catheter insertions. Microbiological analysis revealed A. junii in pleural fluid, sensitive to multiple antibiotics. Successful treatment with meropenem and amikacin resulted in improved hydropneumothorax, leading to the patient’s discharge. Acinetobacter species, primarily opportunistic pathogens, predominantly cause hospital-acquired infections. A. junii, though rare, can lead to severe infections, often associated with nosocomial outbreaks. Notably, our patient, without immunocompromise or critical illness, presented a unique case of A. junii-induced hydropneumothorax, possibly nosocomial in origin. This case underscores the significance of recognizing rare pathogens like A. junii, even in nonimmunocompromised patients. Early identification facilitates prompt treatment, contributing to improved outcomes when coupled with appropriate supportive management. This report adds to the understanding of the diverse clinical presentations of Acinetobacter species.
- 1 January 2025
- Published by Wolters Kluwer Health in The Journal of Association of Chest Physicians
- Vol. 13 (1) , 3-6
Open AccessHydropneumothorax Caused by Acinetobacter junii in an Immunocompetent Patient with No Comorbidities: A Rare Case Report
Acinetobacter junii, a rare human pathogen, poses a challenge in identification due to its complex diagnostic requirements. While generally nonfatal, it can lead to severe infections, often affecting immunocompromised individuals. We present a case of a 32-year-old nonsmoking make farmer with a 6-year history of progressive breathlessness, cough, and right-sided chest pain. Diagnosed with right-sided pneumothorax, the patient underwent pigtail and Mallecot’s catheter insertions. Microbiological analysis revealed A. junii in pleural fluid, sensitive to multiple antibiotics. Successful treatment with meropenem and amikacin resulted in improved hydropneumothorax, leading to the patient’s discharge. Acinetobacter species, primarily opportunistic pathogens, predominantly cause hospital-acquired infections. A. junii, though rare, can lead to severe infections, often associated with nosocomial outbreaks. Notably, our patient, without immunocompromise or critical illness, presented a unique case of A. junii-induced hydropneumothorax, possibly nosocomial in origin. This case underscores the significance of recognizing rare pathogens like A. junii, even in nonimmunocompromised patients. Early identification facilitates prompt treatment, contributing to improved outcomes when coupled with appropriate supportive management. This report adds to the understanding of the diverse clinical presentations of Acinetobacter species.
- Open Access
- 31 December 2024
- Published by Indian Association of Preventive and Social Medicine in Indian Journal of Community Health
- Vol. 36 (6) , 846-851
Assessment of Knowledge, Attitude, and Practices among respiratory patients on inhalation therapy in a tertiary care hospital
Background: Obstructive airway disease (OAD) causes significant morbidity and healthcare expenses. Smoking cessation, drug therapy, and pulmonary rehabilitation reduce morbidity and improve outcomes. However, each strategy requires knowledge, positivity, adherence, compliance, and technique to improve OAD clinical outcomes. Aim and objective: To assess the knowledge and attitude of OAD patients and to evaluate their medication adherence in a tertiary care hospital. Methodology: A north Indian tertiary care hospital conducted this six-month prospective, observational, questionnaire-based investigation. Subjects were asked questions on their disease knowledge, attitude, and drug adherence. Results: 152 patients were analyzed for this study. Here, 80 (51.9%) patients were male and 74(48.1%) were female. Among the subjects, 46.9% (n=72, p=0.0001) have adequate knowledge about their treatment and ailment. Out of the total patients, 71.2% (n=110, p=0.007) have an optimistic attitude towards their treatment, while 42.5% (n=65) of patients adhere to their therapy. Conclusion: OAD patients have low drug adherence. Simplified treatment regimens, self-management education, and provider abilities in patient education, communication, and adherence counseling can solve shortcomings.
- 31 December 2024
- Published by Indian Association of Preventive and Social Medicine in Indian Journal of Community Health
- Vol. 36 (6) , 846-851
Open AccessAssessment of Knowledge, Attitude, and Practices among respiratory patients on inhalation therapy in a tertiary care hospital
Background: Obstructive airway disease (OAD) causes significant morbidity and healthcare expenses. Smoking cessation, drug therapy, and pulmonary rehabilitation reduce morbidity and improve outcomes. However, each strategy requires knowledge, positivity, adherence, compliance, and technique to improve OAD clinical outcomes. Aim and objective: To assess the knowledge and attitude of OAD patients and to evaluate their medication adherence in a tertiary care hospital. Methodology: A north Indian tertiary care hospital conducted this six-month prospective, observational, questionnaire-based investigation. Subjects were asked questions on their disease knowledge, attitude, and drug adherence. Results: 152 patients were analyzed for this study. Here, 80 (51.9%) patients were male and 74(48.1%) were female. Among the subjects, 46.9% (n=72, p=0.0001) have adequate knowledge about their treatment and ailment. Out of the total patients, 71.2% (n=110, p=0.007) have an optimistic attitude towards their treatment, while 42.5% (n=65) of patients adhere to their therapy. Conclusion: OAD patients have low drug adherence. Simplified treatment regimens, self-management education, and provider abilities in patient education, communication, and adherence counseling can solve shortcomings.
- Open Access
- 23 December 2024
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 19
Shifting Paradigms in the Management of Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in 25 mm Hg, has been challenged by observational cohort studies, which have shown poor outcomes for values of 21–24 mmHg; the new consensus is that PH is defined at mPAP >20 mm Hg. Although the gold standard for diagnosis and the major source of therapy guidance continues to be right cardiac catheterisation, echocardiography remains the initial test of choice. A multidisciplinary approach is highly recommended when treating PH patients and careful evaluation of patients will aid in proper diagnosis and prognosis. Pharmacotherapy for PAH has seen a paradigm shift with the successful use of newer agents in more extensive, longer and more inclusive trials driven by hard endpoints. Macitentan, selexipag and riociguat are three oral agents that have shown astounding success in PAH randomised studies in the past decade. Upfront combination therapy with two agents is now becoming the norm (following the AMBITION, OPTIMA and ITALY trials) and the momentum is shifting towards triple therapy as for essential hypertension. More recently, inhaled treprostinil was shown to improve exercise capacity in PH associated with interstitial lung disease in the phase III INCREASE study and has been granted regulatory approval for World Health Organization group 3 PH. A new class of drug, sotatercept (a tumour growth factor-β signalling inhibitor), has also been recently approved by the Food and Drugs Administration for management of PAH based on positive results from the phase III STELLAR study. Pulmonary artery denervation and balloon pulmonary angioplasty have emerged as viable alternatives in PH that are resistant to drug therapy. This article aims to summarise the key changes and recent advances in diagnosis and managing PH in general, with an emphasis on certain subgroups.
- 23 December 2024
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 19
Open AccessShifting Paradigms in the Management of Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in 25 mm Hg, has been challenged by observational cohort studies, which have shown poor outcomes for values of 21–24 mmHg; the new consensus is that PH is defined at mPAP >20 mm Hg. Although the gold standard for diagnosis and the major source of therapy guidance continues to be right cardiac catheterisation, echocardiography remains the initial test of choice. A multidisciplinary approach is highly recommended when treating PH patients and careful evaluation of patients will aid in proper diagnosis and prognosis. Pharmacotherapy for PAH has seen a paradigm shift with the successful use of newer agents in more extensive, longer and more inclusive trials driven by hard endpoints. Macitentan, selexipag and riociguat are three oral agents that have shown astounding success in PAH randomised studies in the past decade. Upfront combination therapy with two agents is now becoming the norm (following the AMBITION, OPTIMA and ITALY trials) and the momentum is shifting towards triple therapy as for essential hypertension. More recently, inhaled treprostinil was shown to improve exercise capacity in PH associated with interstitial lung disease in the phase III INCREASE study and has been granted regulatory approval for World Health Organization group 3 PH. A new class of drug, sotatercept (a tumour growth factor-β signalling inhibitor), has also been recently approved by the Food and Drugs Administration for management of PAH based on positive results from the phase III STELLAR study. Pulmonary artery denervation and balloon pulmonary angioplasty have emerged as viable alternatives in PH that are resistant to drug therapy. This article aims to summarise the key changes and recent advances in diagnosis and managing PH in general, with an emphasis on certain subgroups.